Rigel Pharmaceuticals, Inc.RIGLNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
5Y CAGR+25.5%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
+25.5%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
3.1x
Strong expansion
Streak
2 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 42.41% |
| 2024 | -4.66% |
| 2023 | -59.31% |
| 2022 | -7.61% |
| 2021 | 8.55% |
| 2020 | 13.64% |
| 2019 | 12.75% |
| 2018 | 1.37% |
| 2017 | -27.07% |
| 2016 | 0.99% |